Mohamed A Ghonim1, Kusma Pyakurel2, Jihang Ju2, Paulo C Rodriguez2, Matthew R Lammi3, Christian Davis2, Mohammad Q Abughazleh2, Moselhy S Mansy4, Amarjit S Naura5, A Hamid Boulares6. 1. Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, La; Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. 2. Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, La. 3. Pulmonary and Critical Care Section, LSU Health Sciences Center, New Orleans, La. 4. Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. 5. Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, La. Electronic address: anaura@pu.ac.in. 6. Stanley S. Scott Cancer Center, LSU Health Sciences Center, New Orleans, La. Electronic address: hboulr@lsuhsc.edu.
Abstract
BACKGROUND: We reported that DNA-dependent protein kinase (DNA-PK) is critical for the expression of nuclear factor κB-dependent genes in TNF-α-treated glioblastoma cells, suggesting an involvement in inflammatory diseases. OBJECTIVE: We sought to investigate the role of DNA-PK in asthma. METHODS: Cell culture and ovalbumin (OVA)- or house dust mite-based murine asthma models were used in this study. RESULTS: DNA-PK was essential for monocyte adhesion to TNF-α-treated endothelial cells. Administration of the DNA-PK inhibitor NU7441 reduced airway eosinophilia, mucus hypersecretion, airway hyperresponsiveness, and OVA-specific IgE production in mice prechallenged with OVA. Such effects correlated with a marked reduction in lung vascular cell adhesion molecule 1 expression and production of several cytokines, including IL-4, IL-5, IL-13, eotaxin, IL-2, and IL-12 and the chemokines monocyte chemoattractant protein 1 and keratinocyte-derived chemokine, with a negligible effect on IL-10/IFN-γ production. DNA-PK inhibition by gene heterozygosity of the 450-kDa catalytic subunit of the kinase (DNA-PKcs(+/-)) also prevented manifestation of asthma-like traits. These results were confirmed in a chronic model of asthma by using house dust mite, a human allergen. Remarkably, such protection occurred without causing severe combined immunodeficiency. Adoptive transfer of TH2-skewed OT-II wild-type CD4(+) T cells reversed IgE and TH2 cytokine production but not airway hyperresponsiveness in OVA-challenged DNA-PKcs(+/-) mice. DNA-PK inhibition reduced IL-4, IL-5, IL-13, eotaxin, IL-8, and monocyte chemoattractant protein 1 production without affecting IL-2, IL-12, IFN-γ, and interferon-inducible protein 10 production in CD3/CD28-stimulated human CD4(+) T cells, potentially by blocking expression of Gata3. These effects occurred without significant reductions in T-cell proliferation. In mouse CD4(+) T cells in vitro DNA-PK inhibition severely blocked CD3/CD28-induced Gata3 and T-bet expression in CD4(+) T cells and prevented differentiation of TH1 and TH2 cells under respective TH1- and TH2-skewing conditions. CONCLUSION: Our results suggest DNA-PK as a novel determinant of asthma and a potential target for the treatment of the disease.
BACKGROUND: We reported that DNA-dependent protein kinase (DNA-PK) is critical for the expression of nuclear factor κB-dependent genes in TNF-α-treated glioblastoma cells, suggesting an involvement in inflammatory diseases. OBJECTIVE: We sought to investigate the role of DNA-PK in asthma. METHODS: Cell culture and ovalbumin (OVA)- or house dust mite-based murineasthma models were used in this study. RESULTS:DNA-PK was essential for monocyte adhesion to TNF-α-treated endothelial cells. Administration of the DNA-PK inhibitor NU7441 reduced airway eosinophilia, mucus hypersecretion, airway hyperresponsiveness, and OVA-specific IgE production in mice prechallenged with OVA. Such effects correlated with a marked reduction in lung vascular cell adhesion molecule 1 expression and production of several cytokines, including IL-4, IL-5, IL-13, eotaxin, IL-2, and IL-12 and the chemokines monocyte chemoattractant protein 1 and keratinocyte-derived chemokine, with a negligible effect on IL-10/IFN-γ production. DNA-PK inhibition by gene heterozygosity of the 450-kDa catalytic subunit of the kinase (DNA-PKcs(+/-)) also prevented manifestation of asthma-like traits. These results were confirmed in a chronic model of asthma by using house dust mite, a human allergen. Remarkably, such protection occurred without causing severe combined immunodeficiency. Adoptive transfer of TH2-skewed OT-II wild-type CD4(+) T cells reversed IgE and TH2 cytokine production but not airway hyperresponsiveness in OVA-challenged DNA-PKcs(+/-) mice. DNA-PK inhibition reduced IL-4, IL-5, IL-13, eotaxin, IL-8, and monocyte chemoattractant protein 1 production without affecting IL-2, IL-12, IFN-γ, and interferon-inducible protein 10 production in CD3/CD28-stimulated humanCD4(+) T cells, potentially by blocking expression of Gata3. These effects occurred without significant reductions in T-cell proliferation. In mouseCD4(+) T cells in vitro DNA-PK inhibition severely blocked CD3/CD28-induced Gata3 and T-bet expression in CD4(+) T cells and prevented differentiation of TH1 and TH2 cells under respective TH1- and TH2-skewing conditions. CONCLUSION: Our results suggest DNA-PK as a novel determinant of asthma and a potential target for the treatment of the disease.
Authors: Y Gu; K J Seidl; G A Rathbun; C Zhu; J P Manis; N van der Stoep; L Davidson; H L Cheng; J M Sekiguchi; K Frank; P Stanhope-Baker; M S Schlissel; D B Roth; F W Alt Journal: Immunity Date: 1997-11 Impact factor: 31.745
Authors: Lisa Woodbine; Jessica A Neal; Nanda-Kumar Sasi; Mayuko Shimada; Karen Deem; Helen Coleman; William B Dobyns; Tomoo Ogi; Katheryn Meek; E Graham Davies; Penny A Jeggo Journal: J Clin Invest Date: 2013-06-03 Impact factor: 14.808
Authors: Amarjit S Naura; Hogyoung Kim; Jihang Ju; Paulo C Rodriguez; Joaquin Jordan; Andrew D Catling; Bashir M Rezk; Zakaria Y Abd Elmageed; Kusma Pyakurel; Abdelmetalab F Tarhuni; Mohammad Q Abughazleh; Youssef Errami; Mourad Zerfaoui; Augusto C Ochoa; A Hamid Boulares Journal: J Biol Chem Date: 2012-11-26 Impact factor: 5.157
Authors: A A Al-Khami; M A Ghonim; L Del Valle; S V Ibba; L Zheng; K Pyakurel; S C Okpechi; J Garay; D Wyczechowska; M D Sanchez-Pino; P C Rodriguez; A H Boulares; A C Ochoa Journal: Clin Exp Allergy Date: 2017-07-05 Impact factor: 5.018
Authors: Mohamed A Ghonim; Kusma Pyakurel; Salome V Ibba; Amir A Al-Khami; Jeffrey Wang; Paulo Rodriguez; Hamada F Rady; Ali H El-Bahrawy; Matthew R Lammi; Moselhy S Mansy; Kamel Al-Ghareeb; Alistair Ramsay; Augusto Ochoa; Amarjit S Naura; A Hamid Boulares Journal: J Transl Med Date: 2015-07-14 Impact factor: 5.531
Authors: Mohamed A Ghonim; Kusma Pyakurel; Salome V Ibba; Jeffrey Wang; Paulo Rodriguez; Amir A Al-Khami; Matthew R Lammi; Hogyoung Kim; Arnold H Zea; Christian Davis; Samuel Okpechi; Dorota Wyczechowska; Kamel Al-Ghareeb; Moselhy S Mansy; Augusto Ochoa; Amarjit S Naura; A Hamid Boulares Journal: Clin Sci (Lond) Date: 2015-07-23 Impact factor: 6.124
Authors: Matthew R Lammi; Mohamed A Ghonim; Jessica Johnson; Johnny D'Aquin; John B Zamjahn; Andy Pellett; Samuel C Okpechi; Connie Romaine; Kusma Pyakurel; Hahn H Luu; Judd E Shellito; A Hamid Boulares; Bennett P deBoisblanc Journal: Respir Med Date: 2021-03-08 Impact factor: 3.415
Authors: David K Harrison; Zachary J Waldrip; Lyle Burdine; Sara C Shalin; Marie Schluterman Burdine Journal: Transplantation Date: 2021-03-01 Impact factor: 5.385